Sort   by:  
 Page size 
MetabolomicsRBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) pati...

2025-04-15 | MTBLS10792 | MetaboLights
TranscriptomicsTranscriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study
Microarray analysis of transcriptional changes in biopsies of solid tumors from patients treated in a Phase I study with the Cdk inhibitor PHA-793887. 7 patient biopsies pre- and post-treatment in dye swap. Tumors are of different origins, and are described in the accompanying manuscript.
ORGANISM(S): Homo sapiens 
2010-05-28 | E-GEOD-18553 | biostudies-arrayexpress
ProteomicsEvidence for substrate control of Cdk phosphorylation timing during the budding yeast cell cycle1757
The main intention of this project is to investigate how Cdk substrate phosphorylation is ordered during the cell cycle. We want to understand what makes a ‘good’ Cdk substrate that is phosphorylated early during the cell cycle, e. g. to promote S phase, as compared to a ‘bad’ Cdk substrate that is ...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2025-04-10 | PXD054832 | Pride
Phosphoproteomics Cdk inhibition Tmt Cdk Cell cycle 
ProteomicsEvidence for substrate control of Cdk phosphorylation timing during the budding yeast cell cycle 3344
The main intention of this project is to investigate how Cdk substrate phosphorylation is ordered during the cell cycle. We want to understand what makes a ‘good’ Cdk substrate that is phosphorylated early during the cell cycle, e. g. to promote S phase, as compared to a ‘bad’ Cdk substrate that is ...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2025-04-10 | PXD054870 | Pride
Phosphoproteomics Cdk inhibition Tmt Cdk Cell cycle 
MetabolomicsCDK4/6 inhibitor-mediated cell overgrowth triggers an osmotic stress response and chronic p38MAPK activation to promote long-term cell cycle arrest

Cell size and the cell cycle are intrinsically coupled and abnormal increases in cell size are associated with senescence and permanent cell cycle arrest. The mechanism by which overgrowth primes cells to withdraw from the cell cycle remains unknown. We investigate this here using CDK4/6 inhibito...

2025-10-24 | MTBLS5868 | MetaboLights
ProteomicsEvidence for substrate control of Cdk phosphorylation timing during the budding yeast cell cycle 3174
The main intention of this project is to investigate how Cdk substrate phosphorylation is ordered during the cell cycle. We want to understand what makes a ‘good’ Cdk substrate that is phosphorylated early during the cell cycle, e. g. to promote S phase, as compared to a ‘bad’ Cdk substrate that is ...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2025-04-10 | PXD055238 | Pride
Phosphoproteomics Tmt Cdk Cell cycle 
ProteomicsEvidence for substrate control of Cdk phosphorylation timing during the budding yeast cell cycle 2522
The main intention of this project is to investigate how Cdk substrate phosphorylation is ordered during the cell cycle. We want to understand what makes a ‘good’ Cdk substrate that is phosphorylated early during the cell cycle, e. g. to promote S phase, as compared to a ‘bad’ Cdk substrate that is ...
ORGANISM(S): Saccharomyces cerevisiae (Baker's yeast) 
2025-04-10 | PXD054974 | Pride
Phosphoproteomics Tmt Cdk Cell cycle 
TranscriptomicsTranscription profiling of human peripheral blood mononuclear cells treated with a CDK inhibitor
A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinic...
ORGANISM(S): Homo sapiens 
2009-03-28 | E-GEOD-15389 | biostudies-arrayexpress
ModelsGerard2013 - Model 3 - Embryonic-type eukaryotic Cell Cycle regulation based on negative feedback between Cdk/cyclin and APC and competitive inhibition between Cdk/cyclin and securin for polyubiquitylation_1
The eukaryotic cell cycle is characterized by alternating oscillations in the activities of cyclin-dependent kinase (Cdk) and the anaphase-promoting complex (APC). Successful completion of the cell cycle is dependent on the precise, temporally ordered appearance of these activities. A modest level o...
2024-09-02 | BIOMD0000000938 | BioModels
TranscriptomicsCDK inhibitors and flavopiridol profiling on A2780 and MCF7 cells
This SuperSeries is composed of the following subset Series: GSE18486: CDK inhibitors PHA-848125 and PHA-690509 profiling on A2780 GSE18498: CDK inhibitor PHA-793887 profiling on A2780 GSE18501: CDK inhibitor PHA-848125 gene expression profiling on MCF7 cell line GSE18504: Flavopiridol profiling on ...
ORGANISM(S): Homo sapiens 
2010-07-14 | E-GEOD-18552 | biostudies-arrayexpress
Sort   by:  
 Page size